Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 3 2Phase 2 2Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Leukemia 1Hematologic Neoplasms 1

Interventions

pembrolizumab 259Cyclophosphamide 243Specimen Handling 198fludarabine 174Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 121Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82Gemcitabine 79fludarabine phosphate 78Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Radiation 56Fluorouracil 56Azacitidine 56durvalumab 54Radiosurgery 53Temozolomide 47Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × quizartinib × 1 year × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT06769490 2026-02-11

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡